Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies

Toxicology Letters

Volumn 196, Issue 1, 2010, Pages 1-11

  Adler, M ^a   Hoffmann, D ^a   Ellinger Ziegelbauer, H ^b   Hewitt, P ^c   Matheis, K ^d   Mulrane, L ^e   Gallagher, W M ^e   Callanan, J J ^e   Suter, L ^f   Fountoulakis, M M ^f   Dekant, W ^a   Mally, A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c MERCK KGAA   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biomarker; Hepatotoxicity; Liver; NGAL; Preclinical safety assessment; Thiostatin

Indexed keywords

1 (2 TRIFLUOROMETHOXYPHENYL) 2 NITROETHANONE; 1 [4 (4 FLUOROPHENYL) 2,6 DIISOPROPYL 5 PROPYLPYRIDIN 3 YL]ETHANOL; 3 PYRROLIDINEACETIC ACID 5 [[[[4' [IMINO[(METHOXYCARBONYL)AMINO]METHYL][1,1' BIPHENYL] 4 YL]OXY]METHYL] 2 OXO] METHYL ESTER; ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALDOSE REDUCTASE INHIBITOR; ALKALINE PHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; BAY 16; BI 3; BILIRUBIN; CLUSTERIN; CREATININE; EMD 334823; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NEW DRUG; THIOSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; MALE; MARKER GENE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TARGET ORGAN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; WISTAR RAT;

ACUTE-PHASE PROTEINS; ANIMALS; ARYLDIALKYLPHOSPHATASE; BILIARY TRACT; BIOMARKERS, PHARMACOLOGICAL; CLUSTERIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; KININOGENS; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; TOXICITY TESTS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 77952744086     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.03.018     Document Type: Article

References (43)

1. Abraham P., Sugumar E. Increased glutathione levels and activity of PON1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: a defense mechanism?. Exp. Toxicol. Pathol. 2008, 59:301-306.
2. Amacher D.E., Adler R., Herath A., Townsend R.R. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin. Chem. 2005, 51:1796-1803.
3. Bandara L.R., Kelly M.D., Lock E.A., Kennedy S. A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol. Sci. 2003, 73:195-206.
4. Bennett M., Dent C.L., Ma Q., Dastrala S., Grenier F., Workman R., Syed H., Ali S., Barasch J., Devarajan P. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 2008, 3:665-673.
5. Bu D.X., Hemdahl A.L., Gabrielsen A., Fuxe J., Zhu C., Eriksson P., Yan Z.Q. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am. J. Pathol. 2006, 169:2245-2253.
6. Bykov I., Junnikkala S., Pekna M., Lindros K.O., Meri S. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin. Immunol. 2007, 124:213-220.
7. Cole T., Inglis A., Nagashima M., Schreiber G. Major acute-phase alpha(1)protein in the rat: structure, molecular cloning, and regulation of mRNA levels. Biochem. Biophys. Res. Commun. 1985, 126:719-724.
8. Cowland J.B., Muta T., Borregaard N. IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J. Immunol. 2006, 176:5559-5566.
9. Feingold K.R., Memon R.A., Moser A.H., Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139:307-315.
10. Ferre N., Camps J., Cabre M., Paul A., Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001, 50:997-1000.
11. Ferre N., Camps J., Prats E., Vilella E., Paul A., Figuera L., Joven J. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 2002, 48:261-268.
12. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., Coll B., Tous M., Joven J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 2006, 45:51-59.
13. Flo T.H., Smith K.D., Sato S., Rodriguez D.J., Holmes M.A., Strong R.K., Akira S., Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921.
14. Fung W.P., Schreiber G. Structure and expression of the genes for major acute phase alpha 1-protein (thiostatin) and kininogen in the rat. J. Biol. Chem. 1987, 262:9298-9308.
15. Gallagher W.M., Tweats D., Koenig J. Omic profiling for drug safety assessment: current trends and public-private partnerships. Drug Discov. Today 2009, 14:337-342.
16. Han W.K., Wagener G., Zhu Y., Wang S., Lee H.T. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin. J. Am. Soc. Nephrol. 2009, 4:873-882.
17. Hidaka S., Kranzlin B., Gretz N., Witzgall R. Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. 2002, 310:289-296.
18. Hillmeister P., Lehmann K.E., Bondke A., Witt H., Duelsner A., Gruber C., Busch H.J., Jankowski J., Ruiz-Noppinger P., Hossmann K.A., Buschmann I.R. Induction of cerebral arteriogenesis leads to early-phase expression of protease inhibitors in growing collaterals of the brain. J. Cereb. Blood Flow Metab. 2008, 28:1811-1823.
19. Hoffmann, D., Adler, M., Vaidya, V., Rached, E., Mulrane, L., Gallagher, W.M., Callanan, J.J., Gautier, J.C., Matheis, K., Staedtler, F., Dieterle, F., Brandenburg, A., Sposny, A., Hewitt, P., Ellinger-Ziegelbauer, H., Bonventre, J.V., Dekant, W. and Mally, A., (2010). Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci, Jan 29 2010 [Epub ahead of print] kfq029 [pii] doi:10.1093/toxsci/kfq029.
20. Hvidberg V., Jacobsen C., Strong R.K., Cowland J.B., Moestrup S.K., Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005, 579:773-777.
21. Jayaraman A., Roberts K.A., Yoon J., Yarmush D.M., Duan X., Lee K., Yarmush M.L. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol. Bioeng. 2005, 91:502-515.
22. Malyszko J., Bachorzewska-Gajewska H., Sitniewska E., Malyszko J.S., Poniatowski B., Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Ren. Fail. 2008, 30:625-628.
23. Mann E.A., Lingrel J.B. Developmental and tissue-specific expression of rat T-kininogen. Biochem. Biophys. Res. Commun. 1991, 174:417-423.
24. Meneses-Lorente G., Guest P.C., Lawrence J., Muniappa N., Knowles M.R., Skynner H.A., Salim K., Cristea I., Mortishire-Smith R., Gaskell S.J., Watt A. A proteomic investigation of drug-induced steatosis in rat liver. Chem. Res. Toxicol. 2004, 17:605-612.
25. Minami K., Saito T., Narahara M., Tomita H., Kato H., Sugiyama H., Katoh M., Nakajima M., Yokoi T. Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol. Sci. 2005, 87:296-305.
26. Mishra J., Ma Q., Kelly C., Mitsnefes M., Mori K., Barasch J., Devarajan P. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr. Nephrol. 2006, 21:856-863.
27. Mishra J., Mori K., Ma Q., Kelly C., Barasch J., Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 2004, 24:307-315.
28. Mitsnefes M.M., Kathman T.S., Mishra J., Kartal J., Khoury P.R., Nickolas T.L., Barasch J., Devarajan P. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr. Nephrol. 2007, 22:101-108.
29. Moreau T., Esnard F., Gutman N., Degand P., Gauthier F. Cysteine-proteinase-inhibiting function of T kininogen and of its proteolytic fragments. Eur. J. Biochem. 1988, 173:185-190.
30. Mori K., Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007, 71:967-970.
31. Mulrane L., Rexhepaj E., Smart V., Callanan J.J., Orhan D., Eldem T., Mally A., Schroeder S., Meyer K., Wendt M., O'Shea D., Gallagher W.M. Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group. Exp. Toxicol. Pathol. 2008, 60:235-245.
32. Nathwani R.A., Pais S., Reynolds T.B., Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005, 41:380-382.
33. Ostapowicz G., Lee W.M. Acute hepatic failure: a Western perspective. J. Gastroenterol. Hepatol. 2000, 15:480-488.
34. Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245:194-205.
35. Rached E., Hoffmann D., Blumbach K., Weber K., Dekant W., Mally A. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol. Sci. 2008, 103:371-381.
36. Roudkenar M.H., Kuwahara Y., Baba T., Roushandeh A.M., Ebishima S., Abe S., Ohkubo Y., Fukumoto M. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J. Radiat. Res. (Tokyo) 2007, 48:39-44.
37. Shannan B., Seifert M., Leskov K., Willis J., Boothman D., Tilgen W., Reichrath J. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006, 13:12-19.
38. Sieber M., Hoffmann D., Adler M., Vaidya V.S., Clement M., Bonventre J.V., Zidek N., Rached E., Amberg A., Callanan J.J., Dekant W., Mally A. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 2009, 109:336-349.
39. Smyth R., Lane C.S., Ashiq R., Turton J.A., Clarke C.J., Dare T.O., York M.J., Griffiths W., Munday M.R. Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell. Biol. Toxicol. 2009, 25:499-512.
40. Sunil V.R., Patel K.J., Nilsen-Hamilton M., Heck D.E., Laskin J.D., Laskin D.L. Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Exp. Mol. Pathol. 2007, 83:177-187.
41. Urban J., Chan D., Schreiber G. A rat serum glycoprotein whose synthesis rate increases greatly during inflammation. J. Biol. Chem. 1979, 254:10565-10568.
42. Wagener G., Gubitosa G., Wang S., Borregaard N., Kim M., Lee H.T. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am. J. Kidney Dis. 2008, 52:425-433.
43. Zidek N., Hellmann J., Kramer P.J., Hewitt P.G. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol. Sci. 2007, 99:289-302.